Nature Communications (Oct 2022)

Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma

  • James T. Topham,
  • Erica S. Tsang,
  • Joanna M. Karasinska,
  • Andrew Metcalfe,
  • Hassan Ali,
  • Steve E. Kalloger,
  • Veronika Csizmok,
  • Laura M. Williamson,
  • Emma Titmuss,
  • Karina Nielsen,
  • Gian Luca Negri,
  • Sandra E. Spencer Miko,
  • Gun Ho Jang,
  • Robert E. Denroche,
  • Hui-li Wong,
  • Grainne M. O’Kane,
  • Richard A. Moore,
  • Andrew J. Mungall,
  • Jonathan M. Loree,
  • Faiyaz Notta,
  • Julie M. Wilson,
  • Oliver F. Bathe,
  • Patricia A. Tang,
  • Rachel Goodwin,
  • Gregg B. Morin,
  • Jennifer J. Knox,
  • Steven Gallinger,
  • Janessa Laskin,
  • Marco A. Marra,
  • Steven J. M. Jones,
  • David F. Schaeffer,
  • Daniel J. Renouf

DOI
https://doi.org/10.1038/s41467-022-33718-7
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 13

Abstract

Read online

KRAS wildtype metastatic pancreatic ductal adenocarcinoma (mPDAC) could represent a distinct molecular entity from other PDACs. Here, the authors analyse KRAS wildtype mPDAC tumours using genomics and transcriptomics and find molecular similarities with cholangiocarcinomas.